= Emerging. More than 5 years before clinical availability. (24.37%, 2023)
= Expected to be clinically available in 1 to 4 years. (39.50%, 2023)
= Clinically available now. (36.13%, 2023)
MSACL 2023 : Pearce

MSACL 2023 Abstract

Self-Classified Topic Area(s): Proteomics
Podium Presentation in Steinbeck 1 on Wednesday at 14:40 (Chair: Zuzana Demianova / Xin Cong)

Cancelled; WD on 3/10/2023
Towards a Who-IFCC Traceable LC-MS/MS-based Assay for Isoform-independent Measurement of Lipoprotein(a)

Ryan W. Pearce, Timothy S. Collier
Quest Cardiometabolic Center of Excellence at Cleveland HeartLab, Cleveland, OH, USA

Ryan Pearce, PhD (Presenter)
Quest Diagnostics

Abstract

This abstract has been withdrawn from presentation.

Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesQuest Diagnostics
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no